In CRC, dasatinib has shown significant anti-proliferative activity in a subset of CRC cell lines, particularly those with increased Src expression at baseline, but its effectiveness as a single treatment in metastatic CRC is limited [102,103]. This evidence concerns the gene SRC and colorectal carcinoma.